👋 Hey, let’s get into it. The CDC’s vaccine advisory drama just claimed another casualty.

Robert Malone, one of the most outspoken members of the newly reshaped ACIP, has stepped down after weeks of mounting tension, legal setbacks, and some very public back-and-forth with HHS. His exit comes just days after a federal judge effectively froze the committee’s recent overhaul, throwing its future into limbo.

Translation: the vaccine policy world is not just messy, it’s borderline gridlocked.

🤖 Lilly Doubles Down on AI With $2.75B Insilico Pact
Eli Lilly is leaning even harder into AI drug discovery, expanding its partnership with Insilico Medicine in a deal worth up to $2.75 billion. The agreement builds on earlier collaborations and gives Lilly deeper access to Insilico’s platform to develop oral therapeutics across undisclosed targets. The structure includes $115 million upfront plus milestones and royalties, signaling long-term commitment rather than a one-off experiment. Lilly has been aggressively stacking AI capabilities, including its Nvidia supercomputer push, and this deal reinforces a clear strategy: if algorithms can shorten timelines, Lilly wants to own that edge.

🤧 Novartis Bets $2B on Next-Gen Allergy Blockbuster
Novartis is paying up to $2 billion for Excellergy, a biotech aiming to upgrade the anti-IgE playbook. Its lead asset, Exl-111, is designed to go beyond current therapies like Xolair by shutting down allergic signaling closer to the source. That could mean faster relief, stronger control, and broader use across conditions like asthma and food allergies. Timing matters here: Xolair already pulls in serious revenue, and Novartis is clearly thinking about lifecycle management before competitors do it for them.

💰 Merck Drops $6.7B to Reload Post-Keytruda
Merck is not waiting around for Keytruda’s 2028 patent cliff. The pharma giant is acquiring Terns Pharmaceuticals for $6.7 billion, anchored by TERN-701, an oral therapy for chronic myeloid leukemia. Early data suggests a favorable safety and efficacy profile, plus the convenience edge of oral dosing. It’s still early-stage, but strategically this is about pipeline insurance. When your biggest asset is heading toward LOE, you either build or buy. Merck just chose “buy.”

🧠 Otsuka Makes $1.2B Bet on Psychedelic-Inspired Psychiatry
Otsuka is acquiring Transcend Therapeutics in a deal worth up to $1.2 billion, centered on an MDMA analog designed to treat PTSD. The lead asset, TSND-201, works by enhancing neuroplasticity, potentially offering faster and more durable psychiatric benefits. With breakthrough designation already in hand, the program sits at the intersection of neuroscience and next-gen psych therapies. Big Pharma has been cautiously circling this space, and Otsuka just stepped in with a full commitment.

🇮🇹 Recordati Weighs $12.6B Buyout in Centennial Year
Recordati may be celebrating its 100th birthday with a massive exit. Private equity firm CVC Capital Partners has floated a $12.6 billion buyout offer, aiming to take the Italian pharma private. CVC already holds a significant stake, so this is more consolidation than surprise attack. Still, the move underscores a broader trend: steady, mid-sized pharma companies are increasingly becoming PE targets as investors look for reliable cash flows in a volatile market.

🪓 Takeda Targets $1.3B Savings.
A sweeping restructuring plan will cut costs and includes layoffs as Takeda prepares for upcoming launches.

✅ Biogen Wins Spinraza Upgrade.
FDA clears a high-dose regimen, cutting loading doses in half and speeding treatment timelines.

💪 Novo’s Triple-G Gains Ground.
Midphase diabetes data looks competitive, but Lilly still leads the next-gen metabolic race.

🧬 Rocket Scores Gene Therapy Approval.
Kresladi gets FDA nod for a rare pediatric disease, plus a valuable priority review voucher.

🫁 AstraZeneca Delivers COPD Win.
Phase 3 data shows reduced exacerbations, validating a mechanism others struggled with.

🎯 Corcept Lands First Approval.
Its ovarian cancer drug Lifyorli wins FDA clearance after a previous setback.

⛓️‍💥 Denali Breaks Rare Disease Slump.
FDA approves first Hunter syndrome therapy addressing cognitive symptoms.

Biotech is having a moment in Washington… and not the good kind.

Last week, industry leaders took to Capitol Hill with a message that sounds less like lobbying and more like a warning: U.S. biotech leadership is at risk. The concerns center on a three-headed monster of policy pressure: drug pricing reform, regulatory unpredictability, and rising global competition, especially from China.

At the heart of the debate is the “Most Favored Nation” policy, which aims to tie U.S. drug prices to those in other countries. On paper, it is a win for affordability. In practice, industry voices argue it could choke off innovation by shrinking the financial upside that fuels R&D. Pair that with the Inflation Reduction Act’s pricing timelines, particularly the so-called pill penalty for small molecules, and you get a growing fear that capital will simply flow elsewhere.

And some data suggests that might already be happening. Venture investment in certain drug categories has dropped sharply, with investors becoming more selective in areas exposed to government pricing pressure. Add in an FDA environment that many describe as increasingly inconsistent, and the risk profile starts to look less like biotech and more like roulette.

Meanwhile, China is not waiting. Faster trials, aggressive funding, and a more centralized system are helping it close the innovation gap. The U.S. still leads, but the margin is shrinking.

The takeaway: this is no longer just a healthcare debate. It is a competitiveness play. And if policymakers miscalculate, the world’s “medicine cabinet” might start stocking shelves somewhere else.

That is how much Ionis slashed the price of Tryngolza, dropping it from $595,000 to $40,000 annually ahead of a broader market push. The move signals a shift from ultra-rare pricing strategy to volume play, as the company eyes a much larger patient population. Same drug, completely different commercial game plan.

Here’s what biotech Redditors are talking about:

👎 Fast Hiring ≠ Good Hiring
One Reddit user warned that lightning-fast hiring can signal internal chaos. Others agreed, noting some companies rush offers because turnover is high or roles are poorly defined. The takeaway: speed feels good, but it can come with hidden tradeoffs once you are inside.

🤷 Is This Just a Biotech Market Correction?
Another thread zoomed out, pointing to COVID-era overinvestment, rising interest rates, and regulatory uncertainty as key drivers of today’s slowdown. The spiciest take: China’s faster clinical timelines and funding momentum could reshape global biotech leadership if Western markets do not stabilize. Optimism exists, but it is cautious at best.

🐷 Pig Semen Powers Eye Cancer Breakthrough.
Researchers used pig-derived exosomes to deliver cancer drugs via eye drops, successfully treating retinal tumors in mice.

💉 GLP-1s Eye Addiction Treatment.
Early research suggests obesity drugs could also help treat substance use disorders.

🤖 Surgical Robot Expands U.S. Reach.
CMR Surgical launches its Versius Plus system stateside after treating 45,000 patients globally.

🫀 Philips AI Guides Heart Repairs.
New FDA-cleared software helps doctors place valve implants in real time during complex procedures.

🥚 Neion Bio Turns Eggs Into Drug Factories
Neion Bio is rethinking biologics manufacturing by using chicken eggs as production vessels. Its Raptor platform engineers eggs to act as self-contained bioreactors, enabling scalable, low-cost production of complex therapies like monoclonal antibodies. Fresh out of stealth, the company has already secured a multi-product biosimilar partnership, with upfront cash, milestones, and profit sharing in play. If it works at scale, this could challenge the capital-heavy infrastructure that defines biologics manufacturing today.

🔥 March 31 — National Bunsen Burner Day
Today celebrates the birthday of Robert Bunsen, the chemist behind one of the most iconic tools in science. Invented in the 1850s, the Bunsen burner became a staple of labs worldwide, powering everything from basic chemistry experiments to spectroscopy breakthroughs. Fun fact: Bunsen never patented it, believing science should be shared, not monetized. Also fun fact: most of us still cannot light one on the first try.

Bunsen burner: consistent, reliable, does exactly what you expect. Biotech policy right now: the exact opposite. 😂

That’s all for today. See you Thursday for the next issue. 👋

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead